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Background: Existing evidence suggests that proinﬂammatory cytokines play an intermediary role in postchemotherapy
cognitive impairment. This is one of the largest multicentered, cohort studies conducted in Singapore to evaluate the
prevalence and proinﬂammatory biomarkers associated with cognitive impairment in breast cancer patients.
Patients and methods: Chemotherapy-receiving breast cancer patients (stages I–III) were recruited. Proinﬂammatory
plasma cytokines concentrations [interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, granulocyte–macrophage colony-
stimulating factor, interferon-γ and tumor necrosis factor-α] were evaluated at 3 time points (before chemotherapy, 6 and
12 weeks after chemotherapy initiation). The FACT-Cog (version 3) was utilized to evaluate patients’ self-perceived cogni-
tive disturbances and a computerized neuropsychological assessment (Headminder™) was administered to evaluate
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patients’ memory, attention, response speed and processing speed. Changes of cognition throughout chemotherapy
treatment were compared against the baseline. Linear mixed-effects models were applied to test the relationships of clin-
ical variables and cytokine concentrations on self-perceived cognitive disturbances and each objective cognitive domain.
Results: Ninety-nine patients were included (age 50.5 ± 8.4 years; 81.8% Chinese; mean duration of education = 10.8 ±
3.3 years). Higher plasma IL-1β was associated with poorer response speed performance (estimate: −0.78; 95% conﬁ-
dence interval (CI) −1.34 to −0.03; P = 0.023), and a higher concentration of IL-4 was associated with better response
speed performance (P = 0.022). Higher concentrations of IL-1β and IL-6 were associated with more severe self-perceived
cognitive disturbances (P = 0.018 and 0.001, respectively). Patients with higher concentrations of IL-4 also reported less
severe cognitive disturbances (P = 0.022).
Conclusions: While elevated concentrations of IL-6 and IL-1β were observed in patients with poorer response speed
performance and perceived cognitive disturbances, IL-4 may be protective against chemotherapy-associated cognitive
impairment. This study is important because cytokines would potentially be mechanistic mediators of chemotherapy-
associated cognitive changes.
Key words: breast cancer, cognitive disturbance, chemobrain, cytokines, cognitive impairment, FACT-Cog
introduction
Commonly known in the literature as ‘chemobrain’, chemo-
therapy-associated cognitive impairment is prevalent among
early-stage breast cancer survivors. Although chemotherapeu-
tic agents are unlikely to cross the blood–brain barrier (BBB)
due to their molecular size, it has been alleged that the occur-
rence of neurotoxicity is linked to the proinﬂammatory cyto-
kine pathways. In the brain, cytokines can cause local
inﬂammation through oxidative and nitrosative processes, es-
pecially in the hippocampus and the regions of the brain where
cytokine receptors are abundant. These reactions would conse-
quently lead to the clinical symptoms of cognitive impairment,
including lapses in memory, attention, processing speed and
response speed.
Experimental studies have further demonstrated that proin-
ﬂammatory cytokines may be mediators of chemotherapy-asso-
ciated cognitive changes, and the ﬂuctuations of circulating
cytokines have been suggested to mediate ‘sickness behavior’ in
patients with severe infections or cancer. Proinﬂammatory
markers have also been purported to give rise to a cluster of other
cancer-related or treatment-related symptoms, including pain
and fatigue. Our research group has recently conducted a review
to evaluate the associations between proinﬂammatory biomarkers
and cognition in cancer patients who were treated with chemo-
therapy [1]; currently, evidence suggests that interleukin (IL)-1β,
IL-6, IL-8 and TNF-α contribute to chemotherapy-associated
cognitive impairment. Numerous studies have also evaluated the
association between IL-2, IL-4, IL-10, granulocyte–macrophage
colony-stimulating factor (GM-CSF), interferon (IFN)-γ and cog-
nition, with majority of results being inconclusive. Furthermore,
the role of cytokines in postchemotherapy-cognitive impair-
ment is still controversial because several studies have reported
conﬂicting results with regard to the strength and direction of
the association between changes in cytokine concentrations and
cognition [2–4]. To gain a better understanding of the role that
cytokines play in chemotherapy-associated cognitive changes,
we designed a robust study to evaluate the effect of chemother-
apy-induced inﬂammatory response on breast cancer patients’
cognitive function, as reﬂected by the changes in plasma cyto-
kine concentrations.
patients andmethods
study design and settings
This was a multicenter prospective cohort study conducted at the two largest
ambulatory cancer institutions in Singapore, where ∼70% of the cancer
patients in this country are treated. Singapore is a multiracial country with a
majority population of Chinese (74.2%), Malay (13.2%) and Indian (9.2%),
with English and Chinese being most commonly spoken. The study was
approved by the Institutional Review Board and written informed consent
was obtained from all participants.
patients
Eligible patients: (i) were newly diagnosed with early-stage breast cancer by a
medical oncologist (within 12 weeks of diagnosis), (ii) had no prior exposure
to chemotherapy and radiation treatments, (iii) were scheduled to begin treat-
ment on a standard adjuvant chemotherapy [anthracycline-based (a single-
day chemotherapy regimen comprising 60 mg/m2 doxorubicin and 600 mg/
m2 cyclophosphamide) or taxane-based (75 mg/m2 docetaxel and 600 mg/m2
cyclophosphamide)], (iv) were ambulatory and had good performance status
(Eastern Cooperative Oncology Group score of 0 or 1), (v) were capable of
giving informed consent and (vi) could speak either English or Chinese.
Patients were excluded from the study if breast cancer was a secondary malig-
nancy, or if they exhibited evidence of brain metastasis, psychosis or any
underlying neuropsychiatric illness that might impair their cognitive abilities.
study procedure
Data collection was carried out at three time points at intervals of ∼6 weeks
(Figure 1). For all patients, the ﬁrst time point (T1) was at baseline before
the initiation of chemotherapy. The second time point (T2) was timed at ∼6
weeks after T1 and also coincided with the ﬁrst day of the third cycle of
chemotherapy. The third time point (T3) was ∼12 weeks after T1 when the
standard chemotherapy had been completed. Overall, the approximate dur-
ation between each time point of assessment was 6 weeks.
At T1, baseline demographic data were collected through existing elec-
tronic databases and through patient interviews. At each time point for data
collection, the patients completed both objective and subjective self-reported
neuropsychological assessments. All data collection tools [Headminder™,
The Functional Assessment of Cancer Therapy-Cognitive Function (FACT-
Cog) (version 3), Beck Anxiety Inventory (BAI) and Brief Fatigue Inventory
(BFI)] were available in English or Chinese and were administered by
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trained bilingual interviewers. Details of the assessment tools are included in
supplementary Material S1, available at Annals of Oncology online.
cytokine analysis
At each time point, a 10-ml sample of blood was drawn from the patients
before the administration of chemotherapy, placed in ethylenediaminetetraa-
cetic acid (EDTA) tubes and centrifuged at 1140 g (2500 rpm) for 30 min
within 30–40 min of collection. Plasma was divided into aliquots and stored
aseptically at −80°C until analysis. A panel of nine plasma cytokines—TNF-
α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF and IFN-γ—was quantiﬁed
for each 50 μl of plasma sample using a highly sensitive multiplex immuno-
assay (Luminex®) in triplicate. Details of the immunoassay are included in
supplementary Material S2, available at Annals of Oncology online.
statistical analysis
All statistical analyses were carried out using the SPSS version 20.
Descriptive statistics were used to summarize the demographic and clinical
characteristics of the patients. A simple Friedman’s test was used to compare
the changes in cytokine concentrations within patients across the three
time points. For the evaluation of cognitive changes within individual
breast cancer patients, a reliable change index (RCI) was computed for
Headminder™ scores based on the repeated normative mean and standard
error of the difference to adjust for the practice effect calculated from a refer-
ence group of 28 breast cancer patients who did not receive chemotherapy
(supplementary Table S1, available at Annals of Oncology online). The RCI
compares the changes in individual test scores with changes in a reference
group to determine whether the changes are greater than those that would
be expected from measurement error alone [5], is calculated by subtracting
the score for an earlier assessment (e.g. T1) and the practice effect from a
later assessment (e.g. T2), and then divide the result by the standard error of
the difference in the reference population. RCI was calculated for the
changes of test scores from T1 to T2, T2 to T3 and overall T1 to T3.
The degrees of change in the individual cognitive domains were deﬁned
as follows: (i) an RCI of greater than −1.5 as ‘no change’; (ii) an RCI ranging
from −1.5 to −2.5 as ‘mild impairment’ and (iii) an RCI of less than −2.5 as
‘severe impairment’. This method of evaluating cognitive changes on object-
ive neuropsychological tests has been widely adopted by numerous studies
and is recommended by international guidelines [6–8].
For the evaluation of perceived cognitive changes within individual breast
cancer patients, a drop of 10.6 points in the total FACT-Cog score was con-
sidered to be perceived cognitive impairment. This deﬁnition was adopted
based on our predetermined ‘minimal clinically important difference’
(MCID) of FACT-Cog in our cancer patients [9].
A linear mixed-model analysis was used to examine the relationship be-
tween each proinﬂammatory cytokines with the objective and self-perceived
cognitive impairment over the 12-week study period (from T1 to T3). The
analyses were conducted for the dependent variables in the Headminder™
scores for the four cognitive domains: processing speed, response speed,
memory and attention. For self-perceived cognitive changes, the dependent
variables referred to the total FACT-Cog score. Other than the cytokines of
interest, documented variables that might affect cognitive function were also
included a priori into the mixed model as ﬁxed effects; these variables were
age, years of education, baseline body mass index, fatigue and anxiety [7, 10–
13] and the intercept varied as a random effect by each subject. Model selec-
tion for the linear mixed-effects models was conducted using the Akaike infor-
mation criterion. Visual graphical inspection (skewness, kurtosis, histograms
and normal Q-Q plots) was conducted to ensure that the dependent variables
resemble a normal distribution and can be ﬁtted into the linear mixed model.
results
patients’ characteristics
Ninety-nine breast cancer patients were included in this analysis
(supplementary Table S2, available at Annals of Oncology online).
The mean age of the patients was 50.5 ± 8.4 years. The majority
were Chinese (81.8%), postmenopausal (49.5%), early-stage breast
cancer patients who received anthracycline-based chemotherapy
(70.7%). Before recruitment, majority (90.9%) of the patients had
received surgery (lumpectomy or mastectomy) on the affected
breast. Surgery occurred 36 (±12) days before recruitment.
Plasma concentrations of cytokines across all three time
points are presented in supplementary Table S3, available at
Annals of Oncology online. No statistically signiﬁcant differences
among the cytokine concentrations across the three time points
were observed, with the exception of IL-6. Overall, an increasing
trend in the concentrations of IL-6 was observed from T1 to T3
(P < 0.0001). Notably, a substantial proportion of patients had
IL-2 (53.5%–57.6%), IL-10 (54.5%–63.6%), GM-CSF (37.4%–
45.5%) and IFN-γ (72.7%–82.8%) concentrations that were
below the detection limit throughout T1 to T3, and large inter-
and intrapatient variations were found for GM-CSF (range:
0.00–439.34 pg/ml) and IL-2 (range: 0.00–43.45 pg/ml) concen-
trations. As the concentrations of IL-2, IL-10 and IFN-γ were
mostly below detection limit, the CV of these measurements
were considerably higher (over 40%).
prevalence of objective and self-perceived
cognitive impairment
Overall, with reference to the baseline at T1, a higher proportion
of patients experienced impairments in memory (13.2%) and
Chemotherapy
cycles
Baseline assessment
1The first time-point (T1) was conducted at baseline, within 12 weeks of diagnosis, before the patients received chemotherapy.
 The second time-point (T2) occurred approximately 6 weeks after T1 which also coincided with Cycle 3 of chemotherapy.
 The third time-point (T3) was conducted approximately 6 weeks after T1 upon the completion of standard chemotherapy.
2At each time-point, patients completed a computerised neuropsychological battery (HeadminderTM), the Functional Assessment of Cancer Therapy-Cognitive Function
 Brief Fatigue Inventory and Beck Anxiety Inventory. A 10 ml tube of blood was drawn at each time-point.
Time-point T1 Time-point T2 Time-point T3
During-chemotherapy
assessment
Post-chemotherapy
assessment
Time-points of
assessments1,2
Cycle 1
(Start)
Cycle 4
(End)(3 weeks)
Cycle 2
(6 weeks) (6 weeks)
(3 weeks) (3 weeks) (3 weeks)
Cycle 3
Figure 1. Study procedure.
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attention (7.3%) after the completion of chemotherapy. Fewer
patients seemed to have suffered from processing speed (2.2%)
and response speed (4.2%) impairments (Table 1). Based on the
MCID of FACT-Cog, a total of 29 patients (29.3%) were classi-
ﬁed as experiencing clinically signiﬁcant perceived cognitive im-
pairment. The cross-sectional raw scores of the tests from T1 to
T3 are presented in supplementary Table S4, available at Annals
of Oncology online.
biological determinants of objective cognitive
function
Every unit increase in plasma IL-1β was associated with a 0.78 de-
crease in the response speed performance [95% conﬁdence inter-
val (CI) −1.34 to −0.03; P = 0.023], and a higher concentration of
IL-4 was associated with better response speed performance
(P = 0.022). No biological predictor for changes in processing
speed, memory and attention was identiﬁed (Table 2).
Overall, age and years of education were associated with object-
ive impairment in the domains of processing speed, response
speed and memory. Patients who were older or less highly edu-
cated experienced more severe impairment in cognitive function.
biological determinants of self-perceived cognitive
function
Higher concentrations of IL-1β and IL-6 were associated with
more severe self-perceived cognitive disturbances (P = 0.018 and
0.001, respectively). Every unit increase in IL-4 concentration was
associated with an estimated 0.95 increase of the FACT-Cog total
score, indicating that patients with higher concentrations of IL-4
reported less severe cognitive disturbances (P = 0.022) (Table 2).
Both anxiety and fatigue were also strong determinants of
self-perceived cognitive impairment; patients with higher levels
Table 1. Prevalence of objective and subjective cognitive
impairment (N = 99)
Cognitive domains Proportion of patients with impairment,N
(%)
From
T1 to T2
From
T2 to T3
Overall
From T1 to T3
Processing speed
Mild impairmenta 1 (1.0) 0 2 (2.2)
Severe impairmentb 2 (2.0) 1 (1.0) 0
Totalc 3 (3.0) 1 (1.0) 2 (2.2)
Response speed
Mild impairmenta 4 (4.0) 8 (8.1) 2 (2.1)
Severe impairmentb 0 1 (1.0) 2 (2.1)
Totalc 4 (4.0) 9 (9.1) 4 (4.2)
Memory
Mild impairmenta 12 (12.1) 5 (5.1) 8 (8.1)
Severe impairmentb 1 (1.0) 4 (4.0) 5 (5.1)
Totalc 13 (13.1) 9 (9.1) 13 (13.2)
Attention
Mild impairmenta 5 (5.1) 4 (4.0) 5 (5.2)
Severe impairmentb 2 (2.0) 0 2 (2.1)
Totalc 7 (7.1) 4 (4.0) 7 (7.3)
FACT-Cog total score
impairmentd 18 (18.2) 24 (24.2) 29 (29.3)
aDefined as a reliable change index of −1.5 to −2.5.
bDefined as a reliable change index of lower than −2.5.
cTotal impairment refers to the number (proportion) of patients with
both mild and severe impairment in that particular cognitive domain.
dSubjective cognitive impairment is defined as a decrease in the
Functional Assessment of Cancer Therapy-Cognitive Function (FACT-
Cog) score of 10.6 points or more, based on the minimal clinically
important difference in FACT-Cog established in a previous study [9].
Table 2. Estimates and standard errors for determinants of objective and subjective cognitive impairment (N = 99)
Parameters Objective measures Subjective measure
Processing speed Response speed Memory Attention FACT-Cog
Est (SE) p-value Est (SE) p-value Est (SE) p-value Est (SE) p-value Est (SE) p-value
Intercept 104.61 (7.73) <0.0001 79.76 (12.5) <0.0001 85.15 (14.6) <0.0001 117.53 (12.0) <0.0001 120.19 (11.7) <0.0001
Clinical determinants
Age −0.096 (0.10) 0.349 −0.514 (0.17) 0.002 0.120 (0.19) 0.535 −0.393 (0.16) 0.014 0.273 (0.15) 0.079
Years of
education
1.199 (0.26) <0.0001 0.629 (0.42) 0.140 1.199 (0.49) 0.017 1.152 (0.40) 0.005 0.390 (0.39) 0.323
Body mass
index
−0.375 (0.18) 0.045 −0.307 (0.30) 0.309 −0.106 (0.35) 0.762 −0.554 (0.29) 0.056 0.035 (0.30) 0.901
Psychosocial determinants
Anxiety −0.014 (0.07) 0.844 0.068 (0.12) 0.564 0.029 (0.16) 0.856 −0.148 (0.11) 0.897 −0.744 (0.14) <0.0001
Fatigue 0.334 (0.25) 0.190 −0.124 (0.42) 0.765 −0.396 (0.56) 0.477 0.394 (0.40) 0.326 −1.568 (0.50) 0.002
Biological determinants
IL-1β −0.218 (0.22) 0.320 −0.778 (0.34) 0.023 −0.206 (0.48) 0.665 −0.240 (0.33) 0.471 −0.915 (0.38) 0.018
IL-4 0.234 (0.20) 0.249 0.760 (0.33) 0.022 0.040 (0.44) 0.933 0.105 (0.30) 0.729 0.949 (0.41) 0.022
IL-6 0.002 (0.01) 0.799 0.013 (0.01) 0.173 0.006 (0.01) 0.671 −0.006 (0.01) 0.579 −0.440 (0.01) 0.001
IL-8 0.004 (0.01) 0.566 0.006 (0.01) 0.581 −0.003 (0.02) 0.877 −0.020 (0.01) 0.078 0.0120 (0.014) 0.387
TNF-α −0.015 (0.09) 0.870 0.103 (0.16) 0.528 0.039 (0.21) 0.856 0.090 (0.15) 0.556 −0.226 (0.19) 0.240
Est, estimate; SE, standard error; FACT-Cog, Functional Assessment of Cancer Therapy-Cognitive Function; IL, interleukin; TNF, tumor necrosis factor.
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of anxiety and fatigue reported more cognitive disturbances
(P < 0.0001 and 0.002, respectively).
discussion
This was one of the largest studies to evaluate the role of proin-
ﬂammatory cytokines in chemotherapy-associated cognitive im-
pairment. An increased concentration of IL-1β was associated
with poorer response speed performance, and it has been widely
reported in the literature that elevated IL-1β concentrations
have been found in patients who manifest neurodegenerative
diseases, such as Alzheimer’s disease and dementia [14, 15].
Increased serum IL-1β concentrations have also been proposed
as a stage marker of ongoing brain neurodegeneration in the
continuum between normal aging and mild cognitive impair-
ment [14]. In animals that were administered IL-1β endogen-
ously, interference in cognitive processes and associated mood
changes were found to be due to the hippocampal production
of IL-1β [16]. IL-6 was also associated with self-perceived cogni-
tive disturbances. These ﬁndings were similar to the results of
another study; signiﬁcant increases in the concentrations of IL-6
and IL-8 were observed in patients who received anthracycline-
based chemotherapy [4]. These patients experienced more severe
self-reported symptoms which included heavy-headedness, dif-
ﬁculty in thinking and problems with concentration. In this
study, an elevated concentration of IL-6 was also associated
with greater perceived cognitive disturbances, which measure
the patients’ perceived lapses in memory, concentration and
mental acuity.
Interestingly, our results suggested that an elevated concentra-
tion of IL-4 was associated with improved response speed per-
formance and self-reported cognitive function. IL-4 plays a
critical role in the higher functions, such as executive functions
and learning, of the brain. The neuroprotective role of IL-4 in
cognitive impairment has been supported by animal studies
[17]. While increases in the concentrations of cytokines such as
IL-1β and IL-6 were observed in aging animals, studies have
shown that this is accompanied by a decrease in the hippocam-
pal production of IL-4 [18]. However, data from human studies
are inconsistent, with two studies unable to depict any relation-
ships between IL-4 and FACT-Cog scores [19, 20]. Furthermore,
these studies were limited by the small size of the cohort
of cancer patients who received different chemotherapeutic regi-
mens. The potential neuroprotective role of IL-4 should be
explored in future studies.
The exact mechanisms behind chemotherapy-induced cyto-
kines and cognitive function are lacking in the literature.
Researchers have proposed that cytokines can penetrate the BBB
readily by active transport through the circumventricular
regions in the brain. In the brain, cytokines may bind to the
endothelial receptors in the brain vasculature to stimulate the
release of other inﬂammatory mediators, such as cell adhesion
molecules, chemokines, nitric oxide and prostaglandins, which
impede the integrity of the BBB and cause structural damage to
the brain [21, 22]. One study observed lower left hippocampal
volume in breast cancer patients; the structural changes were also
associated with higher levels of TNF-α and poorer verbal memory
[3]. To examine the direct effect of cytokines on the brain, one
can assess the concentrations of cytokines in the cerebrospinal
ﬂuid which has direct contact with the brain, however, this ap-
proach may not be feasible in breast cancer survivors.
A key limitation of this study was the lack of concurrent
cancer controls not receiving chemotherapy; thus, a correlation
between cytokine dysregulation and cognitive impairment, and
the progression of cancer was not possible. Nevertheless, the
ﬁnding of an association among exposure to chemotherapy,
plasma concentrations of IL-1β, IL-4 and IL-6 and cognitive
performance in longitudinal outcomes provided support for
the continued examination of postchemotherapy inﬂammation
as an inﬂuential factor in this phenomenon. It would also be
logical to assume that the progression of cancer was less likely
to cause a signiﬁcant ﬂuctuation in cytokine concentrations
among these patients who were diagnosed with early-stage
breast cancer. For future studies, it might be more appropriate
to include both nonchemotherapy-receiving breast cancer con-
trols and healthy controls as references in order to serve as com-
parison [7, 8]. By including both types of controls, the effects of
the cancer itself, aging and the chemotherapy treatment on cog-
nitive changes can be taken into account. Other factors that
could potentially affect cognition were not evaluated in detail
due to the constraints of resources and time within a clinical
setting. Depression, physical activity, the type of surgical proce-
dures and concurrent medications might contribute to changes
in patients’ cytokine levels.
These ﬁndings were only suggestive of a potential association
between cytokines and cognitive function, and the identiﬁed
associations did not equate with causation. In addition to statis-
tical methods, the results must be interpreted based on informa-
tion in the current literature. As discussed in the previous
section, similar studies have identiﬁed the role of IL-1β, IL-4
and IL-8 in neuropsychiatric conditions and chemotherapy-
associated cognitive changes [2–4, 23–25]. Our ﬁndings have
paralleled a proposed mechanism behind the oxidative stress
induced by cytotoxic chemotherapeutic drugs on brain cells that
leads to the clinical presentation of cognitive impairment in
animal models. Results from this exploratory study provide
directions for future research, such as examining whether the
cognitive symptoms observed during chemotherapy treatment
are mediated by inﬂammatory responses.
In conclusion, elevated plasma concentrations of IL-1β might
be associated with poorer respond speed performance during
objective neuropsychological assessments. Elevated concentra-
tions of IL-6 and IL-1β were also observed in patients with
perceived cognitive disturbances. Our results have also suggested
that elevated plasma concentrations of IL-4 are protective
against cognitive impairment. These results are important
because they suggested that cytokines would potentially be
mechanistic mediators of chemotherapy-associated cognitive
changes. With this knowledge, future studies can be focused on
establishing the potential relationship between cytokine dysre-
gulation and other behavioral outcomes, such as fatigue, depres-
sion and anxiety.
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